Market Analysis and Insights: Global Alpha-1-Antitrypsin Antibody Market
Due to the COVID-19 pandemic, the global Alpha-1-Antitrypsin Antibody market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Polyclonal accounting for % of the Alpha-1-Antitrypsin Antibody global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Enzyme Linked Immunosorbent Assay segment is altered to an % CAGR throughout this forecast period.
China Alpha-1-Antitrypsin Antibody market size is valued at US$ million in 2021, while the US and Europe Alpha-1-Antitrypsin Antibody are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Alpha-1-Antitrypsin Antibody landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Alpha-1-Antitrypsin Antibody include Abcam, Thermo Fisher Scientific, Signalway Antibody LLC, LSBio, Boster Biological Technology, NSJ Bioreagents, Santa Cruz Biotechnology, Abnova and G Biosciences, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Alpha-1-Antitrypsin Antibody Scope and Segment
Alpha-1-Antitrypsin Antibody market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Alpha-1-Antitrypsin Antibody market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Polyclonal
Monoclonal
Segment by Application
Enzyme Linked Immunosorbent Assay
Immunohistochemistry Frozen
Western Blot
Others
By Company
Abcam
Thermo Fisher Scientific
Signalway Antibody LLC
LSBio
Boster Biological Technology
NSJ Bioreagents
Santa Cruz Biotechnology
Abnova
G Biosciences
Merck
Creative Diagnostics
United States Biological
Creative Biolabs
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE